Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 13019-3-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#13019-3-AP, RRID:AB_2199414
- Product name
- TFAP2A,AP-2 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated TFAP2A,AP-2 antibody (Cat. #13019-3-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: WB, ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Polymorphism rs2327430 in TCF21 predicts the risk and prognosis of gastric cancer by affecting the binding between TFAP2A and TCF21.
miR-1293 suppresses osteosarcoma progression by modulating drug sensitivity in response to cisplatin treatment.
Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.
The m6A modification-mediated OGDHL exerts a tumor suppressor role in ccRCC by downregulating FASN to inhibit lipid synthesis and ERK signaling.
TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF-β signaling pathway.
Regulation of DEK expression by AP-2α and methylation level of DEK promoter in hepatocellular carcinoma.
Hepatitis B virus X protein promotes human hepatoma cell growth via upregulation of transcription factor AP2α and sphingosine kinase 1.
Zhou X, Shen K, Cao S, Li P, Xiao J, Dong J, Cheng Q, Hu L, Xu Z, Yang L
Cancer cell international 2024 May 7;24(1):159
Cancer cell international 2024 May 7;24(1):159
miR-1293 suppresses osteosarcoma progression by modulating drug sensitivity in response to cisplatin treatment.
Wang T, Huang J, Chen G, Fu J, Li T, Zou X, Yi H
International immunopharmacology 2024 Mar 30;130:111702
International immunopharmacology 2024 Mar 30;130:111702
Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.
Wang C, Zhao Z, Zhao Y, Zhao J, Xia L, Xia Q
Communications biology 2024 Mar 19;7(1):342
Communications biology 2024 Mar 19;7(1):342
The m6A modification-mediated OGDHL exerts a tumor suppressor role in ccRCC by downregulating FASN to inhibit lipid synthesis and ERK signaling.
Shi J, Miao D, Lv Q, Wang K, Wang Q, Liang H, Yang H, Xiong Z, Zhang X
Cell death & disease 2023 Aug 25;14(8):560
Cell death & disease 2023 Aug 25;14(8):560
TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF-β signaling pathway.
Xiong Y, Feng Y, Zhao J, Lei J, Qiao T, Zhou Y, Lu Q, Jiang T, Jia L, Han Y
Cell death & disease 2021 Apr 6;12(4):352
Cell death & disease 2021 Apr 6;12(4):352
Regulation of DEK expression by AP-2α and methylation level of DEK promoter in hepatocellular carcinoma.
Qiao MX, Li C, Zhang AQ, Hou LL, Yang J, Hu HG
Oncology reports 2016 Oct;36(4):2382-90
Oncology reports 2016 Oct;36(4):2382-90
Hepatitis B virus X protein promotes human hepatoma cell growth via upregulation of transcription factor AP2α and sphingosine kinase 1.
Lu ZP, Xiao ZL, Yang Z, Li J, Feng GX, Chen FQ, Li YH, Feng JY, Gao YE, Ye LH, Zhang XD
Acta pharmacologica Sinica 2015 Oct;36(10):1228-36
Acta pharmacologica Sinica 2015 Oct;36(10):1228-36
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The TFAP2A,AP-2 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human TFAP2A,AP-2. This antibody recognizes human, mouse, rat antigen. The TFAP2A,AP-2 antibody has been validated for the following applications: ELISA, WB analysis.
